Myriad Genetics (FRA:MYD) Institutional Ownership: 42.43% (As of Jul. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MYD Myriad Genetics Inc FRA:MYD
58 GF Score
Price €4.33
GF Value €12.24
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Myriad Genetics Institutional Ownership?

Myriad Genetics FRA:MYD -5.65% 58 Institutional Ownership is 42.43% as of Jul. 31, 2026. GuruFocus rates FRA:MYD with a GF Score™ of 58/100 and a GF Value™ of €12.24 (Possible Value Trap). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Myriad Genetics's institutional ownership is 42.43%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Myriad Genetics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Myriad Genetics's Float Percentage Of Total Shares Outstanding is 97.53%.

Myriad Genetics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Myriad Genetics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myriad Genetics Institutional Ownership Chart

Myriad Genetics Historical Data

The historical data trend for Myriad Genetics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 49.21 49.11 49.88 50.52 50.60 51.57 40.66 40.78 40.29 42.43
FRA:MYD
58GF Score
Myriad Genetics Inc FRA:MYD
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Myriad Genetics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 42.43% mean?
Myriad Genetics (FRA:MYD) has a Institutional Ownership of 42.43% as of Jul. 31, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Myriad Genetics and its competitors.
Is Myriad Genetics' Institutional Ownership too high?
Myriad Genetics' current Institutional Ownership is 42.43%. Overall, Myriad Genetics has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Institutional Ownership compare to FLGT and CSTL?
Myriad Genetics' Institutional Ownership of 42.43% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Medical Diagnostics & Research company?
A good Institutional Ownership depends on the Medical Diagnostics & Research industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Myriad Genetics and its competitors. Myriad Genetics's current Institutional Ownership is 42.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (FRA:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €12.24, compared to a current price of €4.33 — trading 64.7% below its estimated fair value. The current Institutional Ownership is 42.43%. Myriad Genetics' overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Myriad Genetics (FRA:MYD), the current Institutional Ownership is 42.43% as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Myriad Genetics (FRA:MYD) Overvalued in 2026?

Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued. The current stock price of €4.33 is trading 64.7% below its estimated GF Value™ of €12.24. GuruFocus considers Myriad Genetics to be Possible Value Trap.

Key valuation signals for FRA:MYD:

  • Institutional Ownership: 42.43%
  • GF Value™: €12.24 vs. price of €4.33 (64.7% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the FRA:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Myriad Genetics Business Description

Other Exchanges MYGN:USA0K3W:UK
Address 322 North 2200 West, Salt Lake City, UT, USA, 84116
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
58GF Score

Get the complete analysis for FRA:MYD

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.33
Price
€12.24
GF Value